On April 25, 2025 Dennie Thompson HealthDay Reporter discusses how four specific genes serve as a telltale clue on to how lethal stomach cancers will develop and process overtime. Testing for these genetic mutation could enable doctors to offer more targeted treatments and could potentially spare some patients from going through aggressive surgical or therapy treatments. As the lead researcher Dr. Ulysses Ribeiro stated "not all stomach cancers are equal" he inferred that in today's day and age most gastric cancers are all treated relatively the same way, with surge and chemotherapy. However, they are hoping to identify key molecular difference in order to tailer new treatments to the biology of each individual patient's tumor. During the study researchers analyzed 21 genes in tumor samples taken from 87 patients who had undergone surgery and chemotherapy for stomach cancer. They then compared how mutations within the genes tracked with patients survival. There results consisted with about one-third of patients who had changes in a specific combination of four genes, BRCA2, CDH1, RHOA, and TP53, and with those patients, they were more likely to die from cancer or have it return slowly. With that genetic combination it contained well-established cancer drivers like BRCA2 mutations that have also been liked to breast and ovarian cancer along with previously unknown genetic variants. The researchers are now working on matching these findings in order to establish lab tests that would be affordable and accurate to screen tumors for identifying high risk genetic patterns. Dr. Ulysses Ribeiro is scheduled to present his new findings at the Digestive Disease Week meeting on May 3, 2025. This is a tremendous step in new medical findings because Dr. Ribeiro is extremely right, all cancers are different and if there is a way to potentially differentiate them and specifically treat them to the patients biology, could result in increased health. Not to mention helping people finally end their battles with cancer once and for all.
No comments:
Post a Comment